Auris Medical Q2 Loss Widens

(RTTNews) - Swiss biopharmaceutical company Auris Medical Holding AG (EARS) Wednesday reported that second-quarter net loss attributable to owners of the company widened to 10.96 million Swiss francs or $11.71 million, from 4.99 million francs or $5.34 million in the prior-year quarter.

Loss per share also widened to 0.34 francs or $0.26 from last year's 0.26 francs or $0.28.

Research and development expenses increased to 8.75 million francs from 4.20 million francs a year ago, reflecting primarily the progression of the AM-101 Phase 3 clinical development program and preparations for the late stage AM-111 clinical program.

Looking ahead to fiscal 2015, the company continues to project operating expenses in the range of 30.0 million to 35.0 million francs.